Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL466184 | 0.98 | CYP1A2 (0.43) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL2858088 | 0.93 | CYP1A2 (0.47) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Hydrochloric Acid SCHEMBL27468730 | 0.85 | CYP1A2 (0.42) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL9537043 | 0.79 | CYP1A2 (0.41) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL420260 | 0.79 | CYP1A2 (0.41) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL9537041 | 0.79 | CYP1A2 (0.41) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL283955 | 0.78 | SLC6A4 (0.33) | — | |
| SCHEMBL9301362 | 0.78 | CYP1A2 (0.40) | CYP1A2USP2ALDH1A1LMNATSHR | |
| Water SCHEMBL10639693 | 0.78 | CYP1A2 (0.40) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL11143116 | 0.78 | CYP1A2 (0.40) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102066416-A | Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RES & DEV GMBH | 2011-05-18 | — | — | CN | claimed |
| CN-102066416-A | Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RES & DEV GMBH | 2011-05-18 | — | — | CN | disclosed |
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | disclosed |
| CN-101631768-A | Novel prodrugs | SUN PHARMA ADVANCED RES CO LTD | 2010-01-20 | — | — | CN | disclosed |
| EP-1603863-B1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD (IN) | 2010-01-13 | — | — | EP | disclosed |
| EP-1603863-B1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD (IN) | 2010-01-13 | — | — | EP | disclosed |
| US-7635717-B2 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED (IN) | 2009-12-22 | — | — | US | disclosed |
| US-7635717-B2 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED (IN) | 2009-12-22 | — | — | US | disclosed |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED | 2006-07-06 | — | — | US | disclosed |
| EP-1603863-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | Hikal Ltd. (IN) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603863-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | Hikal Ltd. (IN) | 2005-12-14 | — | — | EP | disclosed |
| CN-1626069-A | Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy | WARNER LAMBERT CO (US) | 2005-06-15 | — | — | CN | disclosed |
| WO-2004046085-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
| WO-2004046085-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
| CN-1321083-A | Method for making coated gabapentine or pregabaline particles | LAB PROGRAPHARM (FR) | 2001-11-07 | — | — | CN | disclosed |
| US-4087544-A | Treatment of cranial dysfunctions using novel cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-4024175-A | Cyclic amino acids | WARNER-LAMBERT COMPANY (US) | 1977-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | GABRA1, GABRA6, ACMSD | CYP1A2 499/4885USP2 1057/4885ALDH1A1 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.